MTOR and Alzheimer disease: According to a study conducted by Caccamo et al., RAPA (rapamycin) acts as a modulator of the mTOR pathway and has been found to reduce the levels of Aβ42 in the brains of an animal model AD, this reduction in Aβ42 levels was associated with improved memory and learning abilities (Caccamo et al. 2010).